Golden Spark Corporation held a Selenium Seminar for health care professionals and academia in Los Angeles, California on September 7th, 2014
Golden Spark Corporation held a professional seminar for health care providers and academia in the medical industry on Sunday, September 7th, 2014 at Pacific Palms Resort in City of Industry. This seminar invited professionals in the medical industry to come and discuss the new findings of the PLAS Selenium compound. The presentation of the new PLAS compound was given by Chief Executive Officer and biochemist Daniel Song. Among the attendees were individuals from University of California, Los Angeles (UCLA), University of California, Irvine (UCI), University of Southern California (USC), Children’s Hospital Los Angeles, and other private practices.
Golden Spark Corporation has received Certification of Registration from the U.S. Food and Drug Administration.
Golden Spark Corporation is proud to announce the registration with the U.S. Food and Drug Administration. This is only the first step to introducing our new product PLAS to the US market. Golden Spark Corporation has complied with and followed all industry guidelines for current Good Manufacturing Practices in Manufacturing, Packaging, Labeling, and Holding Operation for Dietary Supplements. With this certification, Golden Spark Corporation plans to begin production of PLAS immediately and launch PLAS as a dietary supplement by September of 2014.
Golden Spark Corporation, a C corporation is incorporated in the State of California, USA. Golden Spark Corporation, mainly engaged in extended research and development, has established its new US headquarters in Southern California and plans to finish the seven year research and development effort for their new selenium compound, PLAS (Polyphenol Low Aromaticity Selenium).
Golden Spark Corporation, in collaboration with Shanghai Spark Pharmaceutical Co., Ltd. has announced the completion of the research and development phase of their new dietary supplement PLAS, a product that based on the new complex PLAS factor (polyphenolic selenium complex preparations).
Shanghai Spark Pharmaceutical Co., Ltd. is a high-tech enterprise registered in the Zhangjiang Hi-Tech Park, Shanghai China, specializing in the application development and therapeutic clinical research of PLAS factor.
This new product, PLAS will have ultra-high and safe concentrations of naturally organic selenium.